Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRAY-02: Olomorasib Plus Immunotherapy in KRAS G12C-Mutant NSCLC
jRCT2071250010Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of olomorasib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Disease-Free Survival (DFS) by Investigator Assessment - Part A and Progression-Free Survival (PFS) by BICR - Part B. Started Apr 2025; status: recruiting.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2071250010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250010.